Leukapheresis Market Size, Trends and Growth Analysis by 2027

The leukapheresis market is projected to grow significantly, reaching an estimated US$ 133.90 million by 2028, up from US$ 74.48 million in 2021. This growth represents a compound annual growth rate (CAGR) of 8.7% from 2021 to 2028.

The expansion of the leukapheresis market can be largely attributed to several factors, including an increase in the number of voluntary blood donors, a rise in the prevalence of hematologic disorders, and a growing elderly population. Nevertheless, the high costs associated with leukapheresis may hinder market growth to some degree.

Leukapheresis is a medical procedure that involves the separation of white blood cells (leukocytes), which play a crucial role in the immune response, from a blood sample. This specialized form of apheresis allows for the extraction of specific blood components, such as red blood cells or platelets, while the remaining blood is returned to the patient's circulation. This technique is particularly beneficial for managing elevated white blood cell (WBC) counts, especially in cases of chronic blood cancers like chronic lymphocytic leukemia (CLL). Additionally, leukapheresis can be performed to collect white blood cells for future transplants, especially during instances of significant WBC count drops due to cancer chemotherapy. Another application of leukapheresis is in the innovative immunotherapy known as chimeric antigen receptor (CAR) T-cell therapy, which is utilized to combat various cancers, including leukemia and prostate cancer. The procedure can be conducted on the patient receiving treatment (autologous apheresis) or on a donor for subsequent transplantation (allogeneic apheresis). Currently, leukapheresis is widely employed for treating numerous conditions and is also valuable for diagnostic purposes, as it enhances the yield of circulating tumor cells.

The leukapheresis market can be categorized based on product type into two main segments: leukapheresis devices and leukapheresis disposables. In 2021, the segment for leukapheresis disposables commanded a larger share of the market. However, it is anticipated that the leukapheresis devices segment will experience a higher CAGR during the forecast period from 2021 to 2028.

When examining the market by application, it is divided into research applications and therapeutic applications. The research applications segment held a larger market share in 2021 and is expected to continue to grow at a faster rate in the coming years.

Furthermore, the leukapheresis market is segmented by end user, which includes pharmaceutical and biotechnology companies, academic and research institutions, blood component providers and blood centers, as well as hospitals and transfusion centers.

In preparing the report on the leukapheresis market, various primary and secondary sources were consulted, including pharmaceutical and biotechnology companies, academic and research institutions, and manufacturing organizations. These sources provided valuable insights into the current trends and future projections of the market.

Overall, the leukapheresis market is poised for substantial growth, driven by increasing demand for blood components, advancements in medical technology, and the rising incidence of blood-related diseases. As the healthcare landscape evolves, the role of leukapheresis in both therapeutic and research settings is expected to expand, further solidifying its importance in modern medicine.